Evaluation of Her2/neu status in carcinomas with amplified chromosome 17 centromere locus

American Journal of Clinical Pathology

Volumn 126, Issue 5, 2006, Pages 709-716

  Troxell, Megan L ^a   Bangs, Charles D ^c   Lawce, Helen J ^b   Galperin, Ilana B ^c   Baiyee, Daniel ^c   West, Robert B ^c   Olson, Susan B ^b   Cherry, Athena M ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast carcinoma; CEP17; erb b2; FISH; Fluorescence in situ hybridization; Her 2 neu; Immunohistochemistry; RARA; Retinoic acid receptor; Smith Magenis syndrome

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA;

ACCURACY; AMPLICON; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CENTROMERE; CHROMOSOME 17; CONTROLLED STUDY; EVALUATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE LOCUS; GENE OVEREXPRESSION; GENE PROBE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMITH MAGENIS SYNDROME; TREATMENT PLANNING; BREAST TUMOR; CASE REPORT; CHROMOSOME ABERRATION; FEMALE; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY;

BREAST NEOPLASMS; CENTROMERE; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, RETINOIC ACID;

EID: 85047695948     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/9EYM6VE58F2YCD9F     Document Type: Article

References (33)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
2. Pauletti G, Dandekar S, Kong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
3. Ross JS, Fletcher JA, Bloom KJ, et al. HER-2/neu testing in breast cancer. Am J Clin Pathol. 2003;120(suppl):S53-S71.
4. Winston JS, Ramanaryanan J, Levine E. HER-2/neu evaluation in breast cancer: are we there yet? Am J Clin Pathol. 2004;121(suppl):S33-S49.
5. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
6. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
7. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003;100:10393-10398.
8. Bertucci F, Borie N, Ginestier C, et al. Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene. 2004;23:2564-2575.
9. Abd El-Rehim D, Ball G, Pinder S, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;116:340-350.
10. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
11. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
12. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
13. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
15. Zarbo RJ, Hammond ME. Conference summary, strategic science symposium: HER-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med. 2003;127:549-553.
16. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16:173-182.
17. Downs-Kelly E, Pettay J, Hicks D, et al. Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol. 2005;29:1505-1511.
18. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 2003;77:109-114.
19. Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005;29:1221-1227.
20. Wang S, Hossein Saboorian M, Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002;15:137-145.
21. Varshney D, Zhou YY, Geller SA, et al. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004;121:70-77.
22. Bose S, Mohammed M, Shintaku P, et al. HER-2/new gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/HER-2/neu polysomy. Breast J. 2001;7:337-344.
23. Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 2004;121:631-636.
24. Gliem T, Flynn H, Jenkins R. An evaluation of specimens with amplified centromere 17 signals in the setting of fluorescent in situ (FISH) HER2 testing in breast cancer [abstract]. J Assoc Genet Technologists. 2005;31:110.
25. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972-1977.
26. Dowsett M, Bartlett J, Ellis I, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:418-423.
27. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst. 2002;94:855-857.
28. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11:6598-6607.
29. Hofmann MK, Gross C, Beyser K, et al. Predictive value of Herceptest IHC and Pathvysion FISH data: analysis from a trastuzumab phase II monotherapy study [abstract]. Proc ASCO. 2003;22:185. Abstract 740.
30. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6:240-246.
31. Pollack J, Perou C, Alizadeh A, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999;23:41-46.
32. Salido M, Tusquets I, Corominas JM, et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res. 2005;7:R267-R273.
33. Ma Y, Lespagnard L, Durbecq V, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res. 2005;11:4393-4399.